BioCentury
ARTICLE | Clinical News

Roche down on Phase III setbacks

December 20, 2014 3:14 AM UTC

Roche (SIX:ROG; OTCQX:RHHBY) fell CHF18.30 to CHF270.40 on Friday after reporting disappointing data from a Phase III trial of breast cancer drug Kadcyla ado-trastuzumab emtansine and discontinuing a Phase III study of gantenerumab to treat prodromal Alzheimer's disease (AD).

In the Phase III MARIANNE trial, topline PFS data showed Kadcyla monotherapy and Kadcyla plus Perjeta pertuzumab both demonstrated non-inferiority, but not superiority, to Herceptin trastuzumab plus taxane chemotherapy when used as first-line therapies. Roche's Genentech Inc. unit developed all three drugs. ...